Good and brief you, on highlights joining and our to programs. Then us. it with Thank touch few clinical off everyone, you start thank morning, plans I'll of of development for update then Kamil. Stuart on hand our review which a I'll a our after Interim Frank Chief then development business, Officer; our will and who commercial results. our our our our Shanler, CFO; Ruffo, Jeff Commercial will financial Head Scientific Wayne, review clinical will timelines. address business
our call. take up your we David the Officer, will the will Gordon, also Q&A open during Chief portion to line of remarks, the our Medical prepared available Dr. questions. be Following
relaunching with XXXX, enter data of to are important a we excited our in on to really year RHOFADE transaction. are and November, sales team We in start across promoting RHOFADE. December, with closed cream, catalyst deal began our Starting also acquired a in few last end worldwide the at a rights October RHOFADE reporting commercial; out and we I'll the we pipeline. which of number updates clinical this
partner. Allergan they Aclaris smoothly, a has and been have to from transition the proceeded good First, integration and
years of dermatology. Second, a in spend with over we as Wayne recently changed of new XX side the our leadership brings business of Jeff Commercial. on appointment experience Jeff pharmaceutical the of Head the commercial with Interim majority
the of for the well. are treatment Intendis, management and held was with and of FINACEA Galderma, medications During prescribed These as States responsibility for Promius, marketing He United his in in METROGEL increasing Canada the sales, career, marketing and the he United has launched LEO general two Pharma. responsible positions Onset both, rosacea. of in States and
Vice President he transaction as role of managed the the us. transition providing addition, of his leadership from a for In RHOFADE Business seamless beginning, Development, in
we realigned finally, with we and we meeting in result national acquisition, the far officially RHOFADE a our data encouraged field are are in than are RHOFADE or X.X% began increase sales now of X-week the higher RHOFADE ending the announce for new X-weeks prescription prescriptions force focused X promoting prescribers. as IQVIA the sales Thus by XX% for indicates first NRXs And after early prior we of ending to February, compared an AAD for a immediately existing NRXs prescriptions the RHOFADE. successful X-weeks trends on primary X TRXs pleased March in emphasis before or as as meeting the the our total force position. that in XXXX Third, experienced March have period we the to X-weeks. and the an quarter on potential the relaunching is targeting detail
quarter the fourth results. Moving to
net fourth net the million. total ESKATA was only, and of which for research of million $XXX,XXX, million revenue consisted quarter, During of sales of RHOFADE $X.X of $X.X contract revenue of which net $X.X sales December was
we product. While our in fourth were continue sales year expectations, ESKATA quarter the long-term believe and to potential of below full for the
our turning items to to a note. few Now pipeline,
a efficacy portfolio alopecia and dermatitis treatment drug and alopecia, to candidates clinical have areata, and and very busy expect exciting safety genetic warts, for year regarding We atopic us of report our and results of multiple the the our from vitiligo. ahead studies of we common of
readout presentation Slide ask as just handing will that our that Australia, confluence common wart that the would inhibitor, coming Phase we what review that to brief to in turn to off of XXXX; If quarter out turn late in I our we is review is Slide of a clinical overview coming time first third the study this an you year. of the pipeline At on I Before a in ATI-XXX our we eyebrow like pike well this provide XXXX. down acquisition have compound as in to clinical it which of have is regular conducted provided. update to our we in to program III next was as MKX the Stu would X, a this known reporting, candidate,
that and this areata year. will atopic in in three readout And respectively third will alopecia trials We have year. we label dermatitis the then and second quarter have vitiligo second of that the alopecia, open quarter readout this androgenetic studies, two
Next concept moving be root of math in-line out quarter on the of MKX will RA second sad in inhibitor will a we an patients a where IND then in filing series proving cohort studies year to the in the and XXXX. be this into
on you the Australian update X. Slides that X I ask to would an turn First, through study; eyebrow and
the presented recall, last initially of As X and I'm the you pictures data recruited to year. patients been may the extension phase were in have of X XX months. further on continued study. December we provide X-months in previously patients, Hair over regrowth in ongoing drug. the and the update photos, continues as improvement you and there pleased a an study X from showed from the last study see has past can of clearly three
XX-year subject XXXX. who approximately has of old first duration. With being years since is a male The areata alopecia X had in a episode eyebrow current loss
of [ph] view, the important have the can views It the had sustained. study drug. also up, X subject to note February re-established to of and the see this end we has ensuing frontal over of the is In in brow-archess side been close little exposure that a regrowth subsequent and As this nice months in slides.
see side this we The throughout in X on subject presented to for been approximately this year nice already X in frontal a the and that study Turning view, in also months. months the again, photos December, is the subsequent has XX view, of were for XX; also drug slide. old X each subjects regrowth
been Now loss slides turning to is areata current XXXX. entering approximately approximately old X months. through areata study. the study for on and drug has to past prior a alopecia duration since therapy of X years this female XX; the XX She The XX-year in had is with prior has
Here impressive at We is and we subject in growth of Again, [indiscernible] has hair see viable. side hairs. therapy [ph] ongoing have to showing this of nice the continued but hair at terminal brow This white regrowth the demonstrate demonstrated mechanism and view looking what beginning we had in the opinion study. and the valus hair of approach terminal regrowth X-months close-up, re-establishment improve with arch. This the view the that is many disease. since results the this is nature area our work particularly these long-standing since our and believe with her maintained extension given topical frontal
this we in we our overall are recall, again. the in important? the as Now may complete within to I slides practice. December oral a of disease broad to tend what a is would bottom loss spectrum alopecia hair few Slide phenotypic in touch loss scalp clinical the loss on spectrum on see why like of own presented you is the which This hair you of depicting hair slide. slide This areata. see is a this If of inhibitor JAK is and of Severe briefly turn programs, that can the including picture to involves you XX, relatively that the targeting category
However, about medical the of areata. about forget sole and drives hair have the loss oral inhibitor the for from of [ph], phenotypic We need majority don't lower an this of scores be in patients be who It or topical degrees there thinking those the unmet represent ongoing post oral can't treatment. these many and continues alopecia to patients disease these simply spectrum, JAK suffering to need qualify even who trials. that patients, is patients
as when of the Slide Foundation's the National this you of decisions XX portion are of various extent Moving indicated and treatment about Treatment XX% paradigm of disease, the you the scalp age can the Alopecia treatment line in therapy; the younger, of left and topical on on point than on made are This involvement often further to if listed see is Areata importance of options patient on is topical the also basis extent you is current the website. the to the as your as hand case less the receive as disease middle. typically slide. first
informing and with extremely the useful typical future of systemic how we of most This is dermatology and with likely treatment is about interesting to oral think topical treatment injections. algorithm disorders flowchart including note, topical. both As the acne psoriasis. in steroid It or to extent type options disease you're of JAK more employ that inhibitors, along potential is increases, possibly this treatments paradigms
So how topicals. about turning is think this we orals and to Slide XX,
and on those the down less oral to candidates severe treatment As course Those therapy topical decrease patients to treatments with see therapy. severe might alopecia bulk for topical be population. oral more disease of of disease you topical treatment younger will step can of course successful time after with potentially areata here, this prevalent represents the or or use a the a
Phase longer since time of in be previously AA tend utility either topical formulation the we evaluate dermatitis but with This long-term an more Since atopic studies to with topical of to important to studies for nature. is and study reported from contrast As today continuous oral risk it's at are maintenance for episodic have show long-term program open-label specifically favorable dataset have not in with was data as the need characterized eyebrow in II the the the share expansion chronic data fact is and potential opportunity such This unique that we the very shared disease. profile to previously This with us a from us treatment these to chronic have studies. although or regiments. which announced, topical diseases patients induction and our blinded, two in by additional topical is blinded, continue this oral allowing therapy this therapy. designed do benefit continue provide to
be require to the will treatment related route topical a patients mention our our example, with can updates shown patients efficacy time treatment treatment I indicates assessed safety efficacy the far have lead atopic trials typically even oral no been reported These at good areata with inhibitor patients chronic As with a tree point. can needs that with alopecia oral JAK our like severe X-X JAK adverse adverse in where efficacy months to-date. ATI-XXX topical X-X the with systemic generally therapy and trials in finish to [ph] beyond on months and Many term MKX an dermatitis inhibitor assessed The could after ongoing growth, are events regrowth hair assess inhibitor of program. in longer recognition photographs limit thus has results disease. events. been a about tolerated, brief lasting long which and well would to serious hair achieve
the rheumatoid arthritis clinical on-track this our XXXX; begin in is acquired is team II and drug Phase to the FDA half new from we ATI-XXX mid-XXXX. of the In for shown in to Phase or [ph], discovery in confluence trial IND investigation expect for Our application for candidate coming second submission I drug a FYXX first XXXX.
such Slide XX, TNF oral established IL-X; targets and are these alpha, biologics ATI-XXX compound alpha cytokine and Turning the to IL-X that If production non-dermatology array and ATI-XXX as all and an a activity on with is anti-IL-Xs of of the targets both, and indications. anti-TNF therapeutic would beta, of listed dermatology be slide. anti-IL-Xs broad well-known believe we and successful, this a
that Turning signals once Slide pXX pathways sitting MKX housekeeping specifically inflammation. beta familiar as such processes. controls be of key may myriad the some pathway. XX, other to functions, of alpha, TNF and you a IL-X and downstream, anti-inflammatory upregulates IL-X pXX drive pro-inflammatory with activated, various
of It is housekeeping of works pathways mouse and pXX. this alpha specifically a target does to activation designed XX, Slide block Slide differently. downstream XX, pathways. we ATI-XXX affect or to hypothesis little other not LPS It model. the in pro-inflammatory works have TNF anti-inflammatory induced a Turning tested functions
global response, valve global disease model. to is ATI-XXX to study similar we what no exhibited know observed was RA in durable In studies both over tachyphylaxis, the that inflammatory this pXX Here CDD-XXX the clinical a course i.e. tachyphylaxis, contrast, in and overtime, inhibitor studies historically inhibition both, of was loss have in which observed with pXX inhibitors. the
the arthritis ulcerative beta stronger in a a to the in protection model, models Turning preservation and bone efficacy IL-X may MKX in targeting we decrease avoiding in preservation caps architecture mouse bone models studied a rare crypt pXX metastasis these ATI-XXX in was demonstrate By mouse traditional with model, [ph] studies in model, and have reduction of issues be it microenvironment. demonstrating XX, action to while in affecting these a colitis maintain Slide model joint which the variety anti-inflammatory a historic therapeutics. of of also of pre-clinical and possible
our our to evaluate update to the year now Shanler, programs. order in [ph] that file to expect in the in We of efficacy cohort clinical this demonstrated Dr. out RA and middle embark it Stuart I hypothesis CSO, have over sad-mad activities them an turn on our the will small Stu? of IND and a we preclinically. will on and who prove patients, provide work
